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Abstract 
Prostate cancer kills one man every 45 minutes. Androgen receptor splice variants (AR-V) 
appear to play a critical role in the progression of metastatic prostate cancer. AR-Vs are 
truncated AR isoforms that lack the AR ligand binding domain and remain constitutively 
active in the absence of androgen, promoting cancer cell proliferation through aberrant 
activation of AR-mediated cell survival pathways. Consequently, AR-Vs have been proposed 
to contribute to not only treatment resistance against anti-androgen therapies, but also radio-
resistance in patients receiving combination androgen deprivation therapy and radiation by 
bolstering DNA repair mechanisms. AR-Vs such as androgen receptor variant 7 (AR-V7) 
have been associated with worse clinical outcomes, however attempts to specifically inhibit 
or prevent formation of AR-Vs have to date been unsuccessful. Thus, novel therapeutic 
strategies are desperately needed to address the action of AR-Vs that drive lethal forms of 
prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is 
one such potential therapeutic avenue, however our understanding of the inner workings of 
the spliceosome, and how it contributes to prostate cancer remains incomplete, reflected in 
the dearth of therapeutic agents able to target the spliceosome. This review outlines our 
current understanding of the role of the spliceosome in the progression of prostate cancer and 
explores the therapeutic utility of manipulating this cellular network to improve patient care. 
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Introduction 
Prostate cancer is the second most frequently diagnosed cancer amongst men worldwide [1], 
with one man dying of prostate cancer every 45 minutes in the United Kingdom [2]. Since the 
pioneering work of Charles Huggins and Clarence Hodges, who first demonstrated the 
benefits of androgen deprivation therapy (ADT) in patients with metastatic prostate cancer 
[3], our understanding of its pathogenesis has increased significantly, particularly with 
regards to the fundamental importance of the androgen receptor (AR) in all stages of disease 
from tumorigenesis, to progression
 
and ultimately treatment resistance and death [4]. 
 
The androgen receptor and prostate cancer 
The AR is a ligand-activated transcription factor that plays a central role in male sexual 
development. It is a member of the steroid and nuclear hormone receptor super-family and is 
encoded by the AR gene located on chromosome Xq12 [5], the transcriptional activity of 
which is modulated by its interactions with more than 200 different transcriptional co-
regulators [6]. In prostate cancer, in addition to these regulators, genomic aberrations such as 
AR copy number gain, mutations and rearrangements are also thought to play a significant 
role in AR gene expression with AR overexpression in particular being key to the 
development and progression of castration resistant prostate cancer (CRPC) [7]. 
 
The full-length product of AR gene transcription was first reported in 1988 [8] and has a 
molecular weight of 110 kDa. The AR is comprised of four discrete functional domains 
(figure 1) namely, an N-terminal transcriptional domain (NTD) which is highly variable and 
inherently disordered [5], a DNA binding domain (DBD) which consists of a highly 
conserved 66-residue core made up of two zinc-nucleated modules [9], a hinge region and a 
C-terminal ligand binding domain (LBD) [10]. Of note, while the C-terminal and DBD have 
been crystalized, the crystal structure of the N-terminus remains elusive, hindering the 
development of N-terminal targeting agents. 
 
Under normal conditions, the AR is sequestered within the cytoplasm by a complex of heat 
shock protein (HSP) chaperones [11] and their co-chaperones such as BCL-2-associated-
athanogene-1L (BAG-1L). In the presence of androgens, namely dihydrotestosterone (DHT), 
and to a lesser degree, testosterone, the AR undergoes conformational change [10] and 
dimerises with other ligand-bound AR to form homodimers. The nuclear localisation of the 
AR is dependent on the AR bipartite nuclear localisation sequence (NLS), which is highly 
conserved between many nuclear receptors and contains two clusters of basic amino acids 
[12]. The NLS is recognised by the transport adaptor proteins, alpha and beta importin, which 
regulate the shuttling of the AR homodimers into the cell nucleus. In addition, the NLS is 
also recognised and bound by dynein, a motor protein that interacts with cellular 
microtubules to enhance AR nuclear translocation via a cytoskeletal transport network [13]. 
Once in the nucleus, AR binds DNA at specific sites known as androgen-response elements 
(ARE) through its DBD. In this way, the AR can up- or down-regulate the transcription and 
activation of various genes, many of which are involved with regulating crucial cellular 
functions such as growth and proliferation. As a consequence of this ability to regulate cell 
survival, persistent activation of the AR has been shown to be a pivotal driving force in the 
carcinogenesis and progression of prostate cancer. Furthermore, inhibition of AR signalling 
through androgen deprivation remains the standard of care in the treatment of prostate cancer 
to this day [14]. However, while nearly all patients initially respond to ADT, the duration of 
response varies from months to years, and ultimately all patients eventually acquire resistance 
and progress to lethal CRPC [15]. 
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CRPC was long thought of as being an androgen independent entity, however more recently 
the continuing importance of the AR in the progression of advanced prostate cancer has been 
better appreciated, culminating in the introduction of abiraterone and enzalutamide into 
routine clinical practise, which have been shown to provide additional survival benefit in 
patients with CRPC [16, 17]. Despite the success of these second-generation AR-targeted 
therapies, treatment resistance continues to be a major challenge, leaving patients with only a 
limited number of meaningful treatment options following disease progression, namely 
taxane chemotherapy, which is not without its limitations such as cytopenia and neurotoxicity 
[18, 19], and targeted therapies that are only efficacious in a subgroup of patients, such as 
PARP inhibitors or carboplatin in homologous repair DNA repair defective prostate cancers 
(as yet unapproved) and PD-1 immune checkpoint targeting for mismatch repair defective 
disease [20]. In addition, with clinical evidence emerging that use of abiraterone at diagnosis 
of castration sensitive prostate cancer (CSPC) provides improved outcome [21, 22], it is 
foreseeable that in the future these agents will be used much earlier in the treatment of 
patients’ cancers and potentially result in resistance to anti-androgens occurring at the time of 
progression from first line therapy rather than as a later event, opening the door to new 
clinical dilemmas. 
 
The many faces of the androgen receptor 
While full-length AR (AR-FL) has been well described in the literature [10, 23], more 
recently a variety of alternate versions of AR have been shown to exist. Evidence for this first 
emerged through the work of Dehm and colleagues who identified two truncated AR 
isoforms lacking the C-terminal domain in 22Rv1 prostate cancer cell lines, encoded by 
mRNAs with a novel exon 2b at their 3′ end [24]. In addition, they demonstrated that these 
AR isoforms remained constitutively active, and maintained the proliferation of 22Rv1 cells 
in the absence of androgen [24]. Since this original work, and with the development of more 
advanced sequencing techniques, numerous other truncated forms of AR have been reported 
[23, 25, 26]. 
 
AR protein expression results from the transcription and translation of the AR gene. 
However, due to the discontinuous nature of eukaryotic genes, with regions of non-coding 
DNA (introns) interspersed between stretches of coding DNA (exons), when first transcribed 
the resultant precursor messenger RNA (pre-mRNA) transcript contains both sequences.  
Therefore prior to translation, nascent pre-mRNA transcripts are edited through the process 
of splicing, removing unwanted introns and producing mature messenger RNA (mRNA) that 
can be correctly translated. 
 
Splicing is performed by complex cellular machinery referred to as the spliceosome, the 
importance of which has recently gained increased recognition with the discovery that 
through the alternative inclusion and exclusion of exons and introns, termed alternative 
splicing, a single gene can encode multiple proteins [27], enabling eukaryotic cells to 
transform a genome that contains only 20,000 genes, into a significantly larger and more 
diverse proteome of approximately 95,000 proteins [28].  
 
As such, awareness of the role of the spliceosome in numerous diseases, including cancer is 
growing. However, our understanding of its underlying biological mechanisms remains 
incomplete, making it an important area of Clinical Research. 
 
The Spliceosome 
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The spliceosome is a dynamic cellular machine composed of small nuclear 
ribonucleoproteins (snRNP) and associated protein co-factors. The biosynthesis and assembly 
of the spliceosome is outlined in Box 1. 
 
Importantly, all major steps in spliceosome formation are reversible, suggesting a proof-
reading mechanism in operation during splicing, with in vitro studies having shown that 
partially assembled spliceosomes are able to disassemble and reassemble onto alternative 
splice sites [29], particularly in the early stages of spliceosome assembly, as commitment to 
splicing increases as spliceosome assembly progresses [29]. 
 
Spliceosome regulation 
The core constituents of the spliceosome complex are able to define exon-intron boundaries, 
however, splicing sequences within nascent mRNA precursors often contain too little 
information to unambiguously define splice sites [30]. In addition, human introns often 
contain sequences with a high degree of similarity to authentic splice sites. As such, 
additional cis- and trans-regulatory factors are required to accurately define exon-intron 
junctions and maintain fidelity. cis-regulatory RNA elements are nucleotide sequences within 
pre-mRNA transcripts that can modify the splicing of the same pre-mRNA transcript in 
which they are located. As such, these sequences are referred to as splicing regulatory 
elements (SREs) and contribute to splicing in a context dependent manner, whereby they  can 
serve as either splicing enhancers or silencers depending on their position within the pre-
mRNA transcript [31]. SREs exert their action by recruiting trans-acting splicing factors, 
auxiliary proteins of the spliceosome such as serine/arginine-rich (SR) proteins and 
heterogeneous nuclear ribonuclear proteins (hnRNP). These proteins interact with core 
components of the spliceosome, often the snRNPs U1 and U2, to either activate or suppress 
the splicing reaction by impacting the early steps of spliceosome assembly. In addition, as 
with SREs, trans-acting splicing factors modify splicing in a context dependent manner. For 
example, SR proteins can promote splicing when bound to SREs located within exons, but 
can inhibit splicing when associated with SREs in introns [32]. 
 
Other factors contributing to splicing regulation include tissue-restricted protein splicing 
factors (such as the neuro-oncological ventral antigen (NOVA) [33] and feminizing gene on 
X (FOX) [34]), the rate of transcription elongation [35], tissue hypoxia [36, 37], heat stress 
[38, 39], genotoxic stress [40], chromatin structure and nucleosome positioning [41]. 
Recently this complexity has been furthered with the finding that not only can most splicing 
factors recognise multiple SREs, but each SRE is often bound by multiple different factors, 
suggesting the presence of a complex network of protein–RNA interactions working 
alongside the spliceosome, regulating splicing to not only protect the proteome from error but 
also to provide cellular plasticity [27]. 
 
Alternative splicing 
Splicing typically occurs at constitutive splice sites containing a consensus sequence. Splice 
site selection is reported to crudely depend on the ‘strength’ of a splice site, with sites that are 
more adjusted to the consensus sequence producing strong splice sites that are more 
efficiently recognised by the spliceosome and selected for over weaker sites. However, 
predominantly through trans-acting splicing factors, the spliceosome’s regulatory network 
can modify the strength of these competing sites by silencing stronger splice sites and 
enhancing weaker ones. In this way, the interplay between these competing spliceosomal 
‘homing’ signals within a nascent pre­mRNA can lead to the preferential selection of non-
canonical splice site and result in alternative splicing. 
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High throughput RNA sequencing studies have shown that alternative splicing is a routine 
biological process, with 90-95% of human multi-exon gene transcripts demonstrating 
alternative splicing events, thereby generating protein diversity [42]. Patterns of alternative 
splicing range from alternative 3’ or 5’ splice site recognition, to retained introns and 
mutually exclusive exons, however cassette exon skipping is the most common event in 
humans [43] (figure 2). 
 
Despite the abundance of alternative splicing events, the functional roles of the many spliced 
isoforms remain uncertain, although we have clear evidence that alternative splicing can play 
key roles in regulating the functions of many proteins [44-46]. While many speculate 
alternative splicing is a fundamental factor in biodiversity and evolution [47], it has also been 
implicated in the pathogenesis of a number of diseases including cancer [43, 48, 49]. 
 
The spliceosome in prostate cancer 
The role of the spliceosome in prostate cancer is currently a major area of current Clinical 
Research. While alternatively spliced variants of the AR that remain constitutively active in 
the absence of androgen are the most well described splicing aberrations in prostate cancer, 
the spliceosome has been implicated in the pathogenesis of prostate cancer in a number of 
other ways (figure 3). 
 
Mutations of spliceosome regulators 
Recurrent somatic mutations in genes encoding splicing factors have been identified in a 
variety of different cancers such as uveal melanoma [50], pancreatic ductal adenocarcinoma 
[51], lung adenocarcinoma [52], breast cancer [53] and prostate cancer [54]. Despite this 
diversity in tumour origin however, most reported spliceosomal mutations occur in one of 
four genes, namely splicing factor 3B subunit 1 (SF3B1), SR protein splicing factor 2 
(SRSF2), U2AF1 and zinc finger RNA-binding motif and serine/arginine-rich 2 (ZRSR2) 
[55]. Of these, mutations of the SF3B1 gene are the most common and have been observed in 
both haematological and solid malignancies [55], including prostate cancer [56]. Its protein 
product, SF3B1, is a core spliceosomal protein that binds upstream of the pre-mRNA branch 
site, and is thought to be required for the recognition of most 3′ splice sites [27]. As such, 
available evidence suggests that SF3B1 mutations are associated with enhanced recognition 
of cryptic 3′ splice sites and favour the formation of alternative spliced protein isoforms [57], 
which are considered an important mechanism of treatment resistance and disease 
progression in CRPC. However, with a reported incidence in the region of 1% in prostate 
cancer [54, 56], the contribution of SF3B1 mutations to treatment resistance may prove to be 
limited. 
 
Alterations in spliceosome regulator activity 
Changes in the activity of splicing factors have been reported to directly impact on 
tumorigenesis and disease progression in prostate cancer. For example, Src-Associated 
substrate in Mitosis of 68 kDa (Sam68) is a nuclear splicing factor involved in regulating the 
splicing of Cyclin D1 (CCND1) [58], which is a central component of cell cycle control. 
However, Sam68 is activated through extracellular signal-regulated kinase (ERK)-mediated 
phosphorylation [59], which is dysregulated in approximately a third of human cancers [60] 
including prostate. As such, Sam68 has been found to be frequently upregulated in prostate 
cancer [45], and consequently has been associated with the increased expression of a 
truncated CCND1b isoform, rather than the canonical CCND1a gene product, which 
promotes the proliferation and survival of prostate cancer cells [45]. 
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Splicing factor upregulation has also been linked with prostatic epithelial-mesenchymal 
transition (EMT) and disease progression in CRPC. Following androgen deprivation, 
upregulation of the splicing factor serine/arginine repetitive matrix 4 (SRRM4) has been 
shown to cause the alternative splicing of RE1-silencing (REST) [61], a neuronal master 
regulator which normally prevents the expression of neuronal genes such as synaptophysin 
(SYP) in non-neuronal cells [62]. Consequently, this produces a truncated form of REST that 
lacks its canonical transcriptional repressor domain and gives rise to a more AR-independent, 
neuroendocrine (NE) phenotype, which confers a poorer prognosis [63]. 
 
As well as directly contributing to disease progression, the upregulation of canonical splicing 
factors has also been shown to be pivotal in the pathogenesis of other drivers of prostate 
cancer, such as oncogenes. The proto-oncogene c-MYC is reported to be overexpressed in up 
to 90% of all primary human prostate cancer lesions [64]. MYC hyperactivation amplifies 
pre-mRNA production leading to stress on the spliceosome [65]. As such, these cancers are 
equally dependent on the availability of splicing factors to sustain proliferation and survival 
as they are on MYC [65], demonstrated by the upregulation of a number of splicing factors 
such as SRSF1, hnRNPA1 and hnRNPA2 in MYC overexpressing tumours, and the 
disruption of many vital cell processes which occurs when they are inhibited [65-68]. 
 
Alternative splicing of cellular signal transduction pathways 
The spliceosome and its associated proteins are involved in the routine operation of a wide 
range of cellular processes including DNA repair, transcription and nonsense-mediated RNA 
decay (NMD). For example, through chromatin immunoprecipitation (ChIP) studies, SF3B1 
and U2AF1 have been shown to interact with BRCA1 following DNA damage [69]. 
 
Kruppel-like factor 6 (KLF6) is a key tumour suppressor gene that is often mutated in 
prostate cancer. It encodes a member of the Kruppel-like family of transcription factors 
which binds DNA and regulates growth-related signal transduction pathways, cell 
proliferation, apoptosis, and angiogenesis [70]. While wild-type KLF6 has inhibitory effects 
on cell growth, a common KLF6 germline single nucleotide polymorphism (IVS1−27 
G>A/IVSΔA) results in the production of an alternatively spliced isoform, KLF6 splice 
variant 1 (KLF6 SV1), which enhances cell proliferation, colony formation, and invasion. 
Furthermore, upregulation of KLF6 SV1 in prostate cancer is associated with worse 
prognosis [44, 71]. 
 
As well as effecting important protein signal transducers, the alternative splicing of cell 
surface receptors leading to aberrant activation of key survival pathways is an equally 
important part of the spliceosome’s contribution to prostate cancer progression. For example, 
the fibroblast growth factor-2 receptor (FGFR2) is a tyrosine kinase receptor which when 
activated by the binding of fibroblast growth factor (FGF), is involved in the regulation of 
numerous key cellular processes such as proliferation and differentiation which contribute to 
cell survival [72]. Under normal physiological conditions, the FGFR2 exist in a number of 
isoforms, which tend to be cell type specific with isoform IIIb expressed in epithelial cells 
and isoform IIIc expressed in mesenchymal cells. In prostate cancer however, this 
distribution has been found to change, with isoform IIIc becoming more prevalent [73]. This 
alters the receptors ligand binding specificity to favour the binding of FGF8b [73], the major 
FGF isoform expressed in prostate cancer and which is thought to have an important role in 
disease progression, as evidenced by its association with higher Gleason grade and clinical 
stage [74]. 
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Splicing therefore impacts on prostate carcinogenesis in a multitude of ways, and while the 
breadth of these splicing changes suggests the key to endocrine therapy resistance is likely to 
be multifactorial, currently the most significant role of the spliceosome in the progression of 
prostate cancer is considered to be its involvement in the generation of alternatively spliced 
AR receptor isoforms. 
 
 
Androgen receptor splice variants 
To date, a number of AR splice variants (AR-V) have been identified and examined in 
metastatic CRPC specimens [25, 75, 76] (figure 1), however of these, AR splice variant 7 
(AR-V7) is the most well studied and has been associated with both an increased risk of 
biochemical relapse [77] and poorer overall survival [75, 78-80]. More recently, AR-V9 has 
been shown to not only be co-expressed with AR-V7, but also shares a common 3' terminal 
cryptic exon [81]. Furthermore, AR-V9 may also lead to the ligand-independent growth of 
prostate cancer cells, with high AR-V9 mRNA expression having been reported to be 
predictive of primary resistance to abiraterone [81], however the clinical significance of this 
remains uncertain. 
 
AR-V7 is a truncated isoform of the canonical AR-FL protein that lacks the AR LBD but 
retains both the AR DBD, which mediates AR dimerization and DNA interactions, and the 
NTD which is responsible for the majority of AR transcriptional activity [82]. Crucially, this 
conformatory change has been shown to maintain AR-V7 in a constitutively active state in 
the absence of an androgen ligand, resulting in persistent tumour cell aberrant AR survival 
signalling [5]. Furthermore, this structural difference may also enable AR-V7 to induce a 
distinct set of transcriptional programs compared to AR-FL. For example, expression of AR-
V7, but not AR-FL, has been positively correlated with the expression of the Ubiquitin 
Conjugating Enzyme E2 C (UBE2C) gene, which encodes a protein required for the 
destruction of mitotic cyclins and cell cycle progression in clinical CRPC specimens [83]. 
However, while this may suggest a shift toward AR-V mediated signalling following anti-
androgen therapy in a subset of CRPC tumours, it should be noted that attempts to 
disentangle the functional role of AR-V7 from that of AR-FL have been challenging and this 
continues to be an area of active investigation, with further evidence being required before 
firm conclusions can be drawn on this possibility. 
 
AR-V7 is the most commonly expressed AR-V [25, 82] and its prevalence increases 
significantly as patients progress to CRPC [26, 84, 85]. This can in part be explained as a 
consequence of treatment with ADT through two mechanisms. Firstly, AR-V7 expression is 
intimately linked with AR gene transcription [77] which is increased approximately 10-fold 
in response to androgen deprivation [82], as such AR-V7 expression is consequently also 
increased. Secondly, as ligand-dependent AR signalling decreases AR-V7 transcription, 
inhibition of AR signalling with ADT results in the loss of this negative feedback and 
upregulates AR-V7 expression [5, 82]. 
 
Ultimately however, the processes determining the expression of AR-V7, as opposed to 
canonical AR-FL, remain unclear, although there is increasing appreciation for the 
importance of the spliceosome in this process. 
 
AR-V7 and the spliceosome 
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The AR-V7 protein product arises from the alternative splicing of AR mRNA at cryptic exon 
3 (CE3) as opposed to the canonical AR-FL 3’ss (figure 1). While AR gene copy number 
gain is considered an important determinant of AR-V7 mRNA levels in CRPC metastases 
[86], this alone does not explain why a proportion of encoded AR mRNA becomes 
alternatively spliced. For example, in LNCap95 cells, which are not reported to possess this 
AR copy gain, AR-V7 RNA is still expressed at levels comparable to VCaP cells where AR 
is amplified [77], whereas the parent cell line LNCaP expresses no AR-V7. Therefore, rather 
than the alternative splicing of AR mRNA occurring because of random splicing error as a 
consequence of increased substrate concentration, this instead points towards the existence of 
a regulatory mechanism responsible for splice site selection. 
 
In preclinical prostate cancer models, Liu and colleagues reported that androgen deprivation 
increases spliceosomal recruitment to the AR gene, facilitating both AR and AR-V7 splicing 
[77]. Furthermore, treatment with the anti-androgen Enzalutamide specifically enhances 
recruitment of a number of splicing factors to the P2 region of the AR mRNA [77] which 
contains the AR-V7 3’ splice site. This group further demonstrated that splicing factors 
U2AF65 and SRSF1 acted as ‘pioneer’ factors, directing the recruitment of the spliceosome 
to the SREs adjacent to the AR-V7 3’ss, and increasing the expression of AR-V7 RNA. 
Interestingly, while knockdown of these splicing factors resulted in a reduction in AR-V7 
RNA levels in both VCAP and LnCap95 cell lines, it did not affect AR-FL levels [77]. 
Coupling this data with the finding that the expression of U2AF65 is increased in CRPC 
compared to primary prostate cancer [87], suggests that U2AF65 in particular may play a key 
role in the progression of CRPC and, more specifically, be important in AR-V7 splicing. 
HnRNP1 has also been proposed as a regulator of AR-V7 splicing, however the evidence for 
this is less conclusive. Work by Nadiminty et al. has shown that overexpression of hnRNPA1 
significantly up-regulates protein levels of AR-V7, while down-regulation both reduces AR-
V7 protein expression and re-sensitises castrate-resistant cell lines to enzalutamide [88]. 
However, hnRNP1 knock-down has also been shown to reduce AR-FL levels [77], 
suggesting that hnRNP1 may serve as a general regulator of AR mRNA splicing rather than 
one specific to AR-V7. 
 
Importantly, and in keeping with the concept of a proof-reading process within the 
spliceosomal network, AR-V7 splicing appears to be a dynamic and plastic process. For 
example, the re-introduction of androgen to androgen-deprived cell lines has been shown to 
repress levels of AR-V7 RNA, with this occurring within 24 hours in VCaP cells. Similarly, 
in primary cultures from enzalutamide-resistant VCaP xenograft models, both AR and AR-
V7 RNA levels significantly decreased when DHT was added [77]. As an interesting aside, it 
may be the rapidity of this plasticity that contributes to the encouraging efficacy 
demonstrated by bipolar androgen therapy (BAT) in a recent phase 2 clinical trial. Teply et al 
observed that 52% of patients with metastatic CRPC that had previously progressed on 
enzalutamide achieved a 50% reduction in PSA following further treatment with 
enzalutamide after having received BAT, where patients receive intermittent doses of high-
dose testosterone whilst remaining on ADT [89]. While this may suggest that re-sensitisation 
of treatment resistant prostate cancer to enzalutamide is potentially possible through 
manipulation of AR-FL and AR-V expression levels by modulating an individual’s exposure 
to testosterone, definitive conclusions regarding this possibility are difficult to elucidate from 
this cohort given that patient AR-V7 status in this study was determined through analysis of 
circulating tumour cells (CTC) rather than tissue-based assessment. As such, because over 
half of the patients included were found to be CTC negative, a large proportion of this cohort 
could not be assessed for AR-V7 status, and so a number of AR-V7 positive patients could 
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have been omitted from analyses. Furthermore, pre-clinical evidence in support of this 
possibility remains inconclusive [90]. 
 
Alternative splicing and treatment resistance 
Over recent years, appreciation for the role of alternative splicing in the development of 
treatment resistance against anti-cancer therapies has greatly increased. For example, 
alternative splicing of Survivin, a member of the inhibitor of apoptosis protein (IAP) family 
has been reported to confer resistance to taxanes in pre-clinical models of ovarian cancer 
[91], while the alternative splicing of B-lymphocyte antigen CD19 may promote resistance to 
immunotherapy with adoptive T cells expressing chimeric antigen receptors (CAR-T) against 
CD19 in pre-clinical models of B-cell acute lymphoblastic leukaemia [92]. 
 
Similarly, even though the development of genome sequencing has heralded the arrival of 
various new targeted anti-cancer therapies, evidence is emerging that these therapeutic agents 
are equally vulnerable to the development of resistance as a consequence of alternative 
splicing. For example, a subset of BRAF mutant melanomas have been reported to acquire 
resistance to vemurafenib through the expression of a variant BRAF isoform, BRAF(V600E), 
which lacks exons 4-8, a region that encompasses the RAS-binding domain [93]. 
Furthermore, and perhaps more pertinently with regards to prostate cancer, alternative 
splicing has been suggested to promote resistance to PARP inhibition [94]. 
 
The PARP inhibitor olaparib utilises the concept of synthetic lethality to exert a therapeutic 
effect in DNA-repair defective cancers by inhibiting Poly (ADP-ribose) polymerase (PARP), 
a protein that is important for repairing DNA single-strand breaks. Inhibiting the repair of 
single strand breaks in this way results in the generation of double strand breaks during cell 
division, which in tumour cells possessing an inherent inability to repair double strand breaks 
due to loss or mutation of DNA-repair proteins such as BRCA1 and 2, results in tumour cell 
death. As such, olaparib has recently been shown to improve overall survival in patients with 
DNA-repair deficient metastatic Prostate cancer with a response rate of 88% in biomarker 
positive patients [20], marking a significant step forward in the management of this patient 
group. PARP inhibition has also demonstrated efficacy in other cancers such as breast [95] 
and ovarian [96], however of note, evidence is emerging from these cancer types to suggest 
alternative splicing may contribute to treatment resistance to olaparib. Wang et al. report that 
a proportion of patients whom possesses PARP-sensitising BRCA1 germline mutations either 
do not respond to, or eventually develop resistance to, PARP inhibition as a result of 
frameshift mutations to exon 11, leading to NMD of full-length BRCA1 and the increased 
expression of an alternatively spliced BRCA1 isoform, BRCA1-Δ11q. In this way, the 
authors suggest that BRCA1 deficient cancer cells utilise mRNA splicing mechanisms to 
remove deleterious germline BRCA1 mutations by producing alternatively spliced protein 
isoforms that retain residual activity and contribute to therapeutic resistance [94]. While it 
should be noted that BRCA2 mutations are much commoner in prostate cancer than BRCA1 
mutations, whether similar patterns and mechanisms of resistance will emerge in prostate 
cancer will be born out through clinical trials of novel targeted therapies such as these. These 
examples do however serve to highlight the clinical implications of alternative splicing and 
add weight to the rationale of harnessing the spliceosome as a novel therapeutic target. 
 
Overall, however, notwithstanding this growing body of literature, currently with regards to 
CRPC, AR-Vs represent the most well-established, and clinically important, mechanism 
through which alternative splicing is thought to contribute to treatment resistance. 
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AR splice variants and treatment resistance 
AR-Vs have been proposed as a biologically credible mechanism of treatment resistance 
through the restoration of AR signalling. Preclinical studies have shown that inhibition of 
AR-V7 can re-sensitise enzalutamide-resistant prostate cancer cell lines to anti-androgen 
treatment [97-99]. Furthermore, AR-Vs have also been implicated in treatment failure in 
patients receiving combined ADT and radiotherapy, with AR-V aberrant signalling bolstering 
the DNA damage response and increasing the clonogenic survival of prostate cancer cells 
after irradiation [100]. 
 
However, the evidence to support AR-Vs role in resistance remains inconclusive. Despite the 
advantageous characteristics conferred by their structural properties, which allow AR-Vs to 
remain constitutively active in the absence of androgen, in practise only a minority of AR-Vs 
have demonstrated this ability in AR transactivation reporter assays [4], raising questions 
regarding the clinical significance of the majority of AR-Vs. A proposed explanation for this 
observation is that most AR-Vs are truncated after exon 3 and lack a complete NLS, therefore 
are expected to be predominantly sequestered within the cytoplasm [101]. AR-V7 is however 
the exception to this rule, and despite having an incomplete NLS, has been shown to have a 
significant nuclear residence time [5]. 
 
AR-Vs have therefore been counter-proposed as being a consequence of the physiological 
response to androgen deprivation. In support of this is the rapidity of their increase following 
ADT. In xenograft models, protein levels of both AR-FL and AR-V7 have been shown to 
increase in just two days following castration and reach peak levels at two weeks, with AR-
V7 mRNA being only a fraction of total AR-FL levels [101]. In addition, the re-introduction 
of androgen in these models returns these levels to baseline in only eight days [101]. Thus, if 
AR-Vs were to cause treatment resistance, one would expect this to occur much sooner than 
seen clinically [16, 17]. In support of this argument, while a number of clinical studies 
corroborate reports that AR-V7 expression confers a worse prognosis and contributes to 
treatment resistance, some groups have failed to validate this relationship. For example, in a 
study by Watson et al. overexpression of AR-V7 in LNCaP cell lines, which do not innately 
express AR-V7, did not confer resistance to enzalutamide both in vitro and in vivo [101]. 
Furthermore, retrospective analyses of patient records by Bernemann et al. identified six out 
of 21 AR-V7 positive patients who experienced a beneficial response to treatment with 
abiraterone or enzalutamide, suggesting a subgroup of AR-V7 positive patients may obtain 
benefit from novel anti-androgen therapy despite detection of AR-V7 splice variants in their 
circulating tumour cells [102]. Similarly, a prospective study by To el al. found no significant 
difference in PSA response nor median PSA progression free survival between AR-V7 and 
AR-V9 positive and negative patients treated with novel anti-androgen therapy, concluding 
that AR-V expression did not predict outcome in metastatic CRPC patients receiving 
abiraterone or enzalutamide [103].  
 
However, it is important to recognise that nearly all studies reported to-date rely on the 
identification of AR-V7 status from CTCs. Therefore, both positive and negative associations 
of AR-V7 expression with clinical outcomes in CRPC have to be interpreted with careful 
consideration of the validity of AR-V7 assays utilised, with multiple lines of evidence clearly 
indicating limitations to these binary assays [75, 79-82, 102, 103]. Firstly, the ability of each 
assay to only determine AR-V7 status (whether mRNA or protein) in patients with CTCs 
needs to be considered; CTC positive AR-V7 negative patients are not the same as CTC 
negative patients in which AR-V7 status cannot be determined, though CTC negative patients 
were recently shown to have the best prognosis after treatment with abiraterone and 
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enzalumaide [104]. Secondly, although assays measuring AR-V7 protein expression 
overcome concerns with regard AR-V7 mRNA stability, they remain susceptible to antibody 
off-target liabilities with the Abcam/Epitomics antibody previously described in the EPIC 
AR-V7 assay having this major limitation [105]. Moreover, consideration needs to be given to 
the possibility that in any one patient there may be large numbers of AR-V7 negative cells 
despite AR-V7 positivity which may mean that these patients will still benefit from 
abiraterone or enzalutamide. Finally, these molecular association studies will need to be 
supported by further understanding of AR-V7 biology and the development of novel 
therapies that abrogate AR-V7 signalling, and induce robust responses in patients with 
CRPC. Only then will the biological and clinical significance of AR-V7 be truly confirmed; 
this remains a priority of for the field and an unmet urgent clinical need. 
 
Utilising the spliceosome to overcome treatment resistance 
There are a number of strategies currently under investigation to therapeutically utilise the 
spliceosome as summarised in table 1. 
 
Targeting the core spliceosome complex 
Through large-scale drug screens, a number of bacterial fermentation products have been 
identified which demonstrate potent anticancer activity through modulation of the core 
spliceosome complex, and can be broadly categorised into three drug classes, namely 
pladienolides, herboxidienes and spliceostatins (table 1). While these compounds are 
structurally distinct, they share a common mechanism of action whereby they all bind SF3B1 
[106]. Under normal conditions, SF3B1 interacts with U2AF65 to recruit U2 to the intron 
3’ss. However, by binding to SF3B1, these compounds interfere with these early stages of 
spliceosome assembly and destabilise the interaction between U2 and its pre-mRNA target, 
modifying splice site selection [107].  This perturbation of U2 also causes an accumulation 
on unspliced pre-mRNA in the cell nucleus, of which a small proportion has been shown to 
‘leak out’ into the cytoplasm and undergo translation, generating aberrant proteins products 
which themselves can be cytotoxic [108, 109]. In addition, a number of these compounds 
have also been shown to decrease levels of vascular endothelial growth factor (VEGF), 
inhibiting tumour angiogenesis in vivo [110]. 
 
However, while the clinical utility of these agents has been well demonstrated in pre-clinical 
studies, for example the dose-dependent growth inhibition seen in prostate cancer xenografts 
following treatment with pladienolide B [111], early phase clinical trial results have been 
more mixed. Two phase 1, open-label, single-arm, dose-escalation studies have assessed the 
pladienolide E7107 in patients with locally advanced or metastatic solid tumours, which 
although showed that E7107 was generally well tolerated and produced both dose-dependent 
and reversible inhibition of pre-mRNA processing in target genes in vivo[112], both were 
suspended as a result of unexpected incidences of bilateral optic neuritis [112, 113]. 
 
H3B-8800, a small molecule modulator of SF3B1 [114] has also entered a phase 1 clinical 
trial (NCT02841540) to determine the maximum tolerated dose and recommended Phase 2 
dose in patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML), 
or Chronic Myelomonocytic Leukaemia (CMML) where recurrent heterozygous mutations of 
SF3B1 are though to play a pathological role. If found to be efficacious in subsequent phase 2 
and 3 trials, H3B-8800 could provide proof of principle that targeting the spliceosome is a 
genuine treatment strategy, and opens the door to a variety of new therapeutic avenues. 
However, the toxicity and tolerability of these agents will equally prove to be important 
factors as to whether or not these agents make their way into routine clinical use. 
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Targeting spliceosomal regulatory proteins 
Rather than target the core spliceosome, an alternative approach to modulating splicing is to 
target its protein regulators. For example, a variety of compounds have been identified that 
can inhibit SR protein phosphorylation, which has been shown in lab models to inhibit 
splicing [115]. TG-003, a benzothiazole, is one such agent and functions as an inhibitor of 
CLK1, CLK2 and CLK4, members of the CDC2-like (or LAMMER) family of dual 
specificity protein kinases. These kinases are typically involved in the phosphorylation of SR 
proteins in the cell nucleus [116], inhibition of which results in the inhibition of splicing and 
dissociation of spliceosomal nuclear speckles [116]. 
 
More recently, bromodomain and extra-terminal (BET) inhibition, a promising therapeutic 
approach currently undergoing clinical evaluation in CRPC (NCT03150056, NCT02711956), 
has also been shown to effect alternative splicing by modulating spliceosomal regulators 
[117]. In a study by Asangani et al. the BET inhibitor JQ1 was found to decrease the 
expression of AR-V7 in pre-clinical models of CRPC by down-regulating the activity of 
splicing factors SRSF1 and U2AF65, and in doing so re-sensitised resistant prostate cancer 
cells to AR targeted therapy [118]. However, as with therapeutic agents targeting the core 
spliceosomal complex, the long-term success of BET inhibition as a clinically useful 
therapeutic modality will hinge on the toxicity profile BET inhibitors demonstrate in ongoing 
clinical trials. 
Other small molecule inhibitors of the spliceosome 
A number of other small molecules have also been identified as being capable of modulating 
the spliceosome, some of which have been reported to have efficacy in cancer. However, 
these studies have generally been limited by their use of cell-free and non-mammalian 
models [119], as such, currently the therapeutic application of these agents is considered 
limited. Despite this, some interesting results have been seen with a number of these agents. 
For example, NB-506, a glycosylated indolocarbazole derivative that inhibits the capacity of 
topoisomerase I to phosphorylate SRFS1, has been shown in vitro to disrupts early 
spliceosome assembly and produces a cytotoxic effect in murine P388 leukaemia cells [120]. 
In addition, anti-tumour activity has also been shown pre-clinically with the biflavonoid 
natural plant product isoginkgetin, at least in part through its ability to interfere with the 
recruitment of the snRNP U4/U5/U6 and inhibiting splicing by precluding the transition from 
spliceosomal complex A to B [121]. 
 
Targeting the spliceosome in oncogene-driven cancers 
As described previously, MYC overexpression places considerable oncogenic stress on the 
spliceosome resulting in cells becoming equally dependent on the spliceosome for survival, 
as they are on MYC. This has led to the hypothesis that in these tumours, inhibition of the 
spliceosome may produce an anticancer effect. In support of this view recently it has been 
reported that in xenograft models of MYC dependent breast cancer, spliceosome 
dysregulation through the inhibition of SF3B1 with sudemycin D increases survival and 
limits metastases [65]. Ultimately however, while intriguing, whether this is a principle will 
be applicable to other similarly important genomic aberrations, or if the clinical utility of this 
approach will be limited to MYC dependent cancers in a subset of tumour types remains to be 
seen. 
 
Targeting alternatively spliced variants 
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When devising therapeutic strategies to target pathological alternatively spliced variants, in 
addition to considering those generated through the action of the spliceosome as discussed 
previously, it is equally important to take into account protein variants resulting from 
alternative means such as genomic fusions or rearrangements which have been described in 
many cancers to impact key proteins including AR and PD-L1 [86]. As such, while targeting 
the spliceosome remains a key consideration in this process, given the multiple routes 
through which alternatively spliced variants can arise, the concept of directly targeting these 
protein variants, rather than their mechanism of origin seems logical. 
 
Efforts to target alternatively spliced proteins remain attractive but doing so directly with 
small molecule inhibitors has to date proved challenging, often due to the inherent nature of 
these alternatively spliced variants. For example, as truncated alternatively spliced AR 
variants lack the AR LBD, alternative target sites are required to facilitate their inhibition. 
However, the disordered nature of the AR NTD, renders a consistent target site difficult to 
ascertain and has hindered drug development along this avenue, requiring the development of 
novel therapeutic strategies. One such approach that has been proposed is the use of 
monoclonal antibodies such as GP369, which specifically blocks the IIIb splice variant of 
FGFR2 [122]. GP369 showed efficacy in inhibiting tumour growth in pre-clinical studies of 
human cancer cell lines and tumour xenografts driven by activated FGFR2 signalling [123], 
however while a phase I trial in patients with advanced stage solid tumours known to express 
FGFR2 was opened (NCT02368951), the trial was terminated early. Despite this setback, the 
ability to target alternatively spliced protein isoforms using monoclonal antibodies may yet 
help circumvent the difficulties associated with directly inhibiting splice variants which have 
hampering drug discovery efforts in this regard to date. 
 
Oligonucleotide therapy 
Oligonucleotide-based therapies utilise engineered oligonucleotides designed to hybridize 
with RNA sequences known to be responsible for specific splicing events, to prevent their 
alternate splicing and the production of pathological erroneous protein products. The 
potential of these therapeutics has so far been best realised in neurodegenerative conditions 
where late-stage clinical trials are underway in Duchenne muscular dystrophy [124] and 
spinal muscular atrophy [125]. However, while the question remains as to whether 
oligonucleotide therapy is a viable treatment approach in cancer, particularly where these 
splicing events are more diverse, evidence in support of this approach stems from work by 
Smith et al. who have developed a novel RNA splice-switching oligonucleotide designed to 
induce skipping of exon 11 of the BRCA1 gene, which is key to the function of BRCA1 in 
DNA damage repair [126]. In doing so the authors report to have successfully rendered wild-
type BRCA1 expressing cell lines more susceptible to PARP inhibitor treatment [126]. 
However, while this provides a fascinating potential therapeutic strategy for targeting 
BRCA1-functional cancers, the challenge in this setting would be to maintain BRCA1 
functionality in non-cancer cells to minimise potentially widespread toxicity. 
 
 
Conclusion 
Splicing events represent a plausible mechanism of treatment resistance and disease 
progression in CRPC and have been proposed as a potential therapeutic target. Drug 
discovery efforts to date have however been challenging and utilising the spliceosome as a 
therapeutic tool seems attractive. However, as yet no spliceosome inhibitors have made an 
impact in prostate cancer clinical practise, largely due to the complexity of the spliceosome, 
and a lack of understanding of its biology. 
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Further research is therefore required to discover the mechanisms underpinning the splicing 
abnormalities thought to contribute to the progression of CRPC, as well as the consequences 
of inhibiting these factors, before the true utility of these therapies can be realised. 
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Fig. 1 |AR splice variants. A schematic diagram depicting the full- length androgen receptor (AR- FL) alongside a 
selection of its truncated protein isoforms, the androgen receptor (AR) splice variants (AR- Vs) AR- V7 , AR- V9, 
and ARv567es. These proteins share identical amino- terminal domains (NTDs) and DNA- binding domains 
(DBDs) but have unique carboxy- terminal extensions. AR- V7 and AR- V9 have a common 3′-terminal cryptic 
exon (CE), while ARv567es has a complete hinge region and nuclear localization signal, similar to that of the full- 
length protein, but lacks a ligand- binding domain (LBD). 
 
 
 
 
 
 
 
 
Fig. 2 |Summary of constitutive and alternative splicing events.a| Graphic depiction of constitutive splicing where 
introns are removed and sequential exons are ligated to produce mature mRNA. b,c| Alternative splicing, in which 
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changes in 5' and 3' splice site selection can result in the generation of alternatively spliced protein variants such 
as androgen receptor (AR) splice variant 7 (AR- V7), which possesses a 3'-terminal cryptic exon. d| Exon 
skipping, in which a cassette exon is spliced out of the nascent mRNA transcript altogether, along with its 
adjacent introns. e| Intron retention; an intron that does not form part of the canonical mRNA transcript is not 
removed and remains within the mature mRNA. f| Splicing, in which complex events that give rise to mutually 
exclusive alternative splicing events, in which only one of a set of two or more exons in a gene is included in the 
final transcript can also occur. Orange exons indicate those that are part of the canonical mRNA sequence; blue 
or purple exons indicate alternative sequences that might or might not be included in the mature mRNA. Black 
lines indicate introns, green lines indicate constitutive splicing patterns, and red lines indicate alternative splicing 
events. 
 
 
 
 
 
Fig. 3 |Mechanisms through which the spliceosome contributes to tumorigenesis and disease progression in 
prostate cancer.a| Alternative splicing of cell- surface receptors such as the FGFR have been reported to cause 
aberrant activation of key survival pathways in the absence of circulating androgens. b| Constitutively active 
splice variants of intracellular transcription factors such as the androgen receptor (AR; red ovals) have been 
linked with disease progression in patients with castration- resistant prostate cancer and are correlated with 
inferior overall survival outcomes. c| Gain- of-function mutations in cis- regulatory elements have been proposed 
to increase AR transcription in the absence of circulating androgens. d| Alternative splicing of key cellular 
regulatory proteins (orange triangles) such as G1–S- specific cyclin D1 (CCND1), a central component of cell 
cycle control, can promote the proliferation and survival of prostate cancer cells. e| Upregulation, as well as 
alternative splicing, of nuclear splicing factors (green circles) such as Kruppel-like factor 6 (KLF6) is able to 
increase cellular proliferation, colony formation, and invasion, as well as epithelial–mesenchymal transition, which 
contributes to AR-independent treatment resistance. 
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Targeting the core spliceosome complex 
 
Targeting spliceosomal regulatory proteins 
 
Other small molecule inhibitors 
 
Agent 
 
Pladienolides 
A–G [127, 
128] 
 
 
E7107 [111] 
 
Herboxidiene 
(GEX1A) [129] 
 
 
FR901463, 
FR901464 and 
FR901465 
[130] 
 
Meayamycin B 
[131] 
 
Spliceostatin 
A [108] 
 
H3B-8800 
[114] 
 
TG003 [116] 
 
SRPIN340 [132] 
 
Cpd-1, Cpd-2 and Cpd-3 
[133] 
 
GSK525762 
[134] 
 
ZEN003694  
[135] 
 
OTX105/MK-
8628 [118] 
 
 
Isoginkgetin [121] 
 
 
 
 
 
NB‑506 [120] 
 
 
Actions 
 
Bind to and inhibit SF3B1 to destabilise 
recruitment of snRNP U2 
 
Decrease levels of VEGF 
 
Cell cycle arrest in G1 and G2/M 
 
Disrupts spliceosome assembly 
 
Generate truncated form of cell cycle inhibitor p27 
which is still functional but more robust 
 
Reduce number of nuclear speckles 
 
Reduced tumour angiogenesis 
 
Small molecule 
modulator of 
SF3B1 
 
Preferential 
lethality toward 
spliceosome-
mutant cancer 
cells due to 
retention of 
short, GC-rich 
introns 
 
Currently in 
Phase I clinical 
trial 
(NCT02841540) 
 
 
Competitive 
antagonist of 
CLK binding of 
ATP 
 
Inhibition of 
CLK enzymatic 
phosphorylation 
and activation 
of splicing 
factors e.g. SR 
proteins 
 
Dissociation of 
nuclear 
speckles 
 
Competitive 
antagonist of 
SRPK1 and 
SRPK2 binding 
of ATP 
 
Nicotinamide 
inhibitor 
 
Inhibits SRPK 
phosphorylation 
and activation of 
splicing factors 
e.g. SR proteins 
 
Modulates 
splicing of 
VEGF 
 
Inhibition of both CLKs 
and SRPKs, components 
of the splicing 
machinery that are 
crucial for exon 
selection 
 
CLK1, CLK2, SRPK1 
and SRPK2 
 
Reduced 
phosphorylation of SR 
proteins 
 
Causes enlargement of 
nuclear speckles 
 
Causes widespread 
splicing alterations 
 
 
Inhibitors of 
bromodomain 
and extra-
terminal (BET) 
proteins BRD2, 
BRD3, BRD4 
and BRDT 
 
Downregulate 
expression of 
splicing factors 
 
Decrease 
alternative 
splicing events in 
pre-clinical 
models 
 
Currently 
ongoing clinical 
evaluation 
(NCT03150056, 
NCT02711956) 
 
Biflavonoid natural 
plant product that 
interferes with the 
recruitment of the 
snRNP U4/U5/U6 
 
 
Prevents transition 
from spliceosomal 
complex A to B 
 
 
 
 
 
Inhibits the SRFS1 
phosphorylation by 
topoisomerase I 
 
In vitro disrupts early 
spliceosome 
assembly and 
produces a cytotoxic 
effect 
Table 1: Small molecules reported to have effect on splicing. snRNP = small nuclear ribonuclearprotein, CLK = CDC2-like kinase; SRPK = serine and 
arginine protein kinase; SRPIN340 = N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl; VEGF = vascular endothelial growth factor. 
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